erlotinib hydrochloride has been researched along with Graft-Versus-Host Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batteux, F; Cerles, O; Chéreau, C; Grange, P; Kavian, N; Marut, W; Morin, F; Nicco, C; Weill, B | 1 |
| Miteva, M; Nusbaum, AG | 1 |
2 other study(ies) available for erlotinib hydrochloride and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Inhibition of EGFR Tyrosine Kinase by Erlotinib Prevents Sclerodermatous Graft-Versus-Host Disease in a Mouse Model.
Topics: Allografts; Analysis of Variance; Animals; Biopsy, Needle; Blotting, Western; CD4-Positive T-Lymphocytes; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Female; Flow Cytometry; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Immunohistochemistry; Interferon-gamma; Interleukin-13; Mice; Mice, Inbred BALB C; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Random Allocation; Reference Values; Scleroderma, Localized | 2015 |
October 2015 Snapshot Dx Quiz: Linking Science to Patient Care.
Topics: Biopsy, Needle; ErbB Receptors; Erlotinib Hydrochloride; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunohistochemistry; Molecular Targeted Therapy; Photography; Prognosis; Scleroderma, Localized | 2015 |